410 / 1031
Treatment volume adaptation
Goal: decreased NTCP, increased TCP by increased dose
I
Tumor regression 0.6%-2.4% per day, high regression results in poor
outcome (in non-adenocarcinoma histology)
I
Noticeable tumor regression in 40% of patients (progression in only 1%),
which was >25% in 17% of the patients in the fourth week (N=114)
I
Tumor shrinkage more pronounced in concurrent as opposed to
sequential RCHT (50.1% versus 33.7%, respectively,
p
=0.003)
I
Treatment planning studies investigating dose escalation resulted in
varying results
Sonke, Belderbos. Sem Radiat Oncol 2011
www.uniklinikum-dresden.deBrink,
et al
., Radiother Oncol 2014
Zwienen,
et al
. Int J Radiat Oncol Biol Phys 2008
Berkovic,
et al
. Acta Oncol 2015